Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe

Boehringer IngelheimBoehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) today announced a new partnership to establish a €2.5 million research grant programme, encouraging diabetes research over the next three years.

The EFSD/Boehringer Ingelheim European Research Programme is intended to stimulate and accelerate research in Europe and encourage new projects aimed at advancing current knowledge in diabetes.

Diabetes is a condition that affects more and more people. "Therefore Boehringer Ingelheim is delighted to partner with the ESFD on this initiative, bringing together two organisations dedicated to improving the lives of people with diabetes", said Professor Klaus Dugi, Corporate Senior Vice President, Boehringer Ingelheim. "As part of our commitment to diabetes patients, we support research that will aid our understanding of the disease and ultimately help to improve therapeutic options for patients, and we hope this grant will support research that otherwise may not be possible."

The grant programme will focus on two areas of interest - pre-clinical research looking into the function of non-insulin peptides secreted by the endocrine pancreas, investigating also the roles, functions and mechanisms of non-β cells; and clinical research which will investigate the mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes.

Prof. Ulf Smith, President of EASD and EFSD, stressed the importance of increasing funding for diabetes research in Europe: "EFSD is proud to establish this valuable cooperation with Boehringer Ingelheim. I hope this partnership will inspire both governments and industry to increase their contributions to research into diabetes."

Applications are invited from single non-profit institutions or groups of institutions in Europe and will be subject to a scientific review by a specialised and independent committee. Researchers who are interested in applying for a grant can download an application form from www.EuropeanDiabetesFoundation.org. Applications can be submitted from January 2012, with the deadline for submission by April 2012.

About Diabetes
Diabetes affects approximately 285 million people worldwide.(1) T2D is the most common type, accounting for an estimated 90 percent of all diabetes cases.(2) Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.(3)

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24 percent of net sales in its largest business segment Prescription Medicines on research and development.

About the EFSD
The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide multiple funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

1. International Diabetes Federation: www.idf.org Last accessed August 2011
2. International Diabetes Federation: Diabetes Prevalence: www.idf.org Last accessed August 2011
3. World Health Organization. Fact sheet N°312.2011: http://www.who.int/mediacentre/factsheets/fs312/en/ Last accessed August 2011

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...